RT Journal Article
SR Electronic
T1 Chemokine Receptor 2 Is A Theranostic Biomarker for Abdominal Aortic Aneurysms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.06.23298031
DO 10.1101/2023.11.06.23298031
A1 Elizondo-Benedetto, Santiago
A1 Sastriques-Dunlop, Sergio
A1 Detering, Lisa
A1 Arif, Batool
A1 Heo, Gyu Seong
A1 Sultan, Deborah
A1 Luehmann, Hannah
A1 Zhang, Xiaohui
A1 Gao, Xuefeng
A1 Harrison, Kitty
A1 Thies, Dakkota
A1 McDonald, Laura
A1 Combadière, Christophe
A1 Lin, Chieh-Yu
A1 Kang, Yeona
A1 Zheng, Jie
A1 Ippolito, Joseph
A1 Laforest, Richard
A1 Gropler, Robert J.
A1 English, Sean J.
A1 Zayed, Mohamed A.
A1 Liu, Yongjian
YR 2023
UL http://medrxiv.org/content/early/2023/11/07/2023.11.06.23298031.abstract
AB Abdominal aortic aneurysm (AAA) is a degenerative vascular disease impacting aging populations with a high mortality upon rupture. There are no effective medical therapies to prevent AAA expansion and rupture. We previously demonstrated the role of the monocyte chemoattractant protein-1 (MCP-1) / C-C chemokine receptor type 2 (CCR2) axis in rodent AAA pathogenesis via positron emission tomography/computed tomography (PET/CT) using CCR2 targeted radiotracer 64Cu-DOTA-ECL1i. We have since translated this radiotracer into patients with AAA. CCR2 PET showed intense radiotracer uptake along the AAA wall in patients while little signal was observed in healthy volunteers. AAA tissues collected from individuals scanned with 64Cu-DOTA-ECL1i and underwent open-repair later demonstrated more abundant CCR2+ cells compared to non-diseased aortas. We then used a CCR2 inhibitor (CCR2i) as targeted therapy in our established male and female rat AAA rupture models. We observed that CCR2i completely prevented AAA rupture in male rats and significantly decreased rupture rate in female AAA rats. PET/CT revealed substantial reduction of 64Cu-DOTA-ECL1i uptake following CCR2i treatment in both rat models. Characterization of AAA tissues demonstrated decreased expression of CCR2+ cells and improved histopathological features. Taken together, our results indicate the potential of CCR2 as a theranostic biomarker for AAA management.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04586452Funding StatementWe would like to thank the preclinical imaging facility for animal PET/CT scans, which is supported by NIH/NCI Siteman Cancer Center (SCC) Support Grant P30CA091842, NIH instrumentation grants S10OD018515 and S10OD030403, and internal funds provided by Mallinckrodt Institute of Radiology. The human imaging was carried out in the Center for Clinical Imaging Research supported by Mallinckrodt Institute of Radiology. RJG is supported by grants from the NIH (R01HL153436, R01HL150891, P41EB025815). MAZ is supported by grants from the NIH (R01HL153436, R01HL150891, R01HL159803, R0153262). YL is supported by grants from the NIH (R01HL153436, R01HL150891, P41EB025815, R35 HL145212).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human 64Cu-DOTA-ECL1i PET/CT study was approved by the Washington University School of Medicine Institutional Review Board (IRB, 202008190).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors